$ALT
Altimmune, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Morristown, NJ
ALT chart
What traders are saying about $ALT
Latest postsAltimmune, Inc. news
- Voting power is shared, not sole, in State Street’s reported Altimmune (ALT) stake.
Stock Titan ·
- Altimmune, Inc. (ALT) Stock Price, News, Quote & History
Yahoo! Finance Canada ·
- Altimmune's Pemvidutide Meets Primary Endpoint in Phase 2 Alcohol Use Disorder Trial
Yahoo Finance ·
- Altimmune Reports Positive Phase 2 RECLAIM Results for Pemvidutide in Alcohol Use Disorder and Announces FDA Meeting Plans for Phase 3 Program
Quiver Quantitative ·
- Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use Disorder
Yahoo Finance ·
- Altimmune (ALT) Institutional Ownership 2026 $ALT
MarketBeat ·
- Altimmune (ALT) Shares Fall Ahead of Pemvidutide Phase 2 Data Pr
GuruFocus ·
- Altimmune to present alcohol use disorder trial data Monday By Investing.com
Investing.com Nigeria ·
- Altimmune presents positive Phase 2 trial data for pemvidutide in alcohol use disorder at AASLD 2026.
Pluang ·
- Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026
Yahoo Finance ·
- Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
Yahoo Finance ·
- Director receives 160,000 stock options at Altimmune (ALT), exercisable at $2.02 a share.
Stock Titan ·
Altimmune, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $41,000 | $20,000 | $426,000 | -$68,000 |
| Net income | -$88.1M | -$95.1M | -$88.4M | -$84.7M |
| Diluted EPS | $-1.00 | $-1.34 | $-1.66 | $-1.81 |
| Total assets (year end) | $279.9M | $139.3M | $210.6M | $206.9M |
| Cash and equivalents (year end) | $43.8M | $36.9M | $135.1M | $111.1M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Altimmune, Inc.
- Ticker
- ALT (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Morristown, NJ
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1326190
- Former names
- PHARMATHENE, INC, HEALTHCARE ACQUISITION CORP
Frequently asked questions
What exchange is Altimmune, Inc. listed on?
Altimmune, Inc. trades on the Nasdaq under the ticker symbol ALT.
What industry is Altimmune, Inc. in?
Altimmune, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Altimmune, Inc. headquartered?
Altimmune, Inc.'s business address on file with the SEC is in Morristown, NJ.
When does Altimmune, Inc.'s fiscal year end?
Altimmune, Inc.'s fiscal year ends on December 31.
How much revenue did Altimmune, Inc. report?
Altimmune, Inc. reported $41,000 in revenue for calendar year 2025, according to its SEC filings.